Search clinical trials for: ALXN1101

Total 36 results

Alexion Pharmaceuticals

Terminated

Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Czech Republic, Italy, Poland, United Kingdom
Origin Biosciences

Completed

Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

Molybdenum Cofactor Deficiency (MoCD) | Rare Autosomal Recessive Disorder | Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)

United States
Origin Biosciences

Completed

Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP

Molybdenum Cofactor Deficiency, Type A

United States, Australia, Netherlands, United Kingdom, Tunisia
Origin Biosciences

Completed

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

Molybdenum Cofactor Deficiency, Type A

United States, Spain, Israel, Norway, Turkey, United Kingdom
Alexion Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects

Healthy Subjects

United States
Alexion

Completed

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants

Healthy

United Kingdom
Alexion

Completed

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

Healthy

United States
Alexion Pharmaceuticals

Terminated

A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease (GIGVHD)

Acute Graft-Versus-Host Disease | GIGVHD

United States, France
Alexion Pharmaceuticals

Terminated

Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome

Antiphospholipid (aPL)-Positive

United States, Italy, Brazil, France, Japan, United Kingdom
Alexion

Completed

A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants

Healthy

United Kingdom
Military Institute od Medicine National Research...
ABM Industries

Recruiting

Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19. (COVMENT)

Nervous System Diseases

Poland
Alexion Pharmaceuticals, Inc.

Completed

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

United States, France, Spain, Taiwan, United Kingdom, Australia, Belgium, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Austria, Canada
Alexion Pharmaceuticals, Inc.

Completed

A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants

Healthy

United Kingdom
Alexion

Active, not recruiting

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

United States, Australia, Austria, Canada, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Spain, United Kingdom
Alexion Pharmaceuticals

Completed

Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria | PNH

Korea, Republic of, Canada, France, Germany, Spain, Taiwan, United Kingdom
Alexion Pharmaceuticals, Inc.

Completed

Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

Italy, United States, Korea, Republic of, Spain, Germany, Belgium, United Kingdom
Alexion

Completed

A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

France, United Kingdom, Norway, Russian Federation, Netherlands, United States
Alexion Pharmaceuticals

Completed

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH

Korea, Republic of, Australia
Alexion Pharmaceuticals, Inc.

Active, not recruiting

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

Dermatomyositis

United States, Spain, Korea, Republic of, United Kingdom, Germany, Italy, France, Japan
Alexion

Completed

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Korea, Republic of, Canada, France, Germany, Spain, United Kingdom, Japan, Australia, Italy, Netherlands
Alexion Pharmaceuticals

Terminated

An Efficacy and Safety Study of Ravulizumab in ALS Participants

Amyotrophic Lateral Sclerosis | ALS

United States, Spain, Italy, Belgium, Canada, Switzerland, Australia, Germany, Denmark, Israel, Sweden, France, Ireland, United Kingdom, Japan, Netherlands, Poland
Alexion

Recruiting

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Neuromyelitis Optica Spectrum Disorder

France, United States, Japan, Spain, Canada, Korea, Republic of, Italy
Alexion

Completed

Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Paroxysmal Nocturnal Hemoglobinuria

Belgium, Brazil, France, Italy, Spain, Australia, Canada, Sweden, Russian Federation, Austria, United States, Netherlands, Turkey, Finland
Alexion

Completed

A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants

Healthy

United Kingdom
Alexion

Completed

A Study of a Single Dose of ALXN1210 in Healthy Participants

Healthy

Canada
Alexion Pharmaceuticals

Completed

Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom
Alexion

Completed

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States, Spain, Korea, Republic of, Austria, Canada, Czechia, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Portugal, Switzerland
Alexion

Completed

ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Belgium, France, Italy, Japan, Spain, Taiwan, United Kingdom, United States, Canada, Czechia, Germany, Sweden, Singapore, Korea, Republic of, Russian Federation, Austria, Poland, Argentina, Australia, Brazil, Estonia, Malaysia, Mexico, Thaila... and more
Alexion Pharmaceuticals, Inc.

Terminated

Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger

Thrombotic Microangiopathy

United States, Belgium, France, Italy, Japan, Spain, Taiwan, United Kingdom, Canada, Korea, Republic of, Netherlands
Alexion Pharmaceuticals

Terminated

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

Pneumonia, Viral | Acute Respiratory Distress Syndrome | Acute Lung Injury | COVID-19 Severe Pneumonia

United States, Spain, United Kingdom, France, Japan
Alexion Pharmaceuticals, Inc.

Recruiting

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

Thrombotic Microangiopathy

United States, Italy, Spain, Korea, Republic of, United Kingdom, Belgium, Netherlands, Germany, Japan, Greece, Brazil, Israel, France, Sweden, Australia, Canada, Poland
Alexion Pharmaceuticals, Inc.

Completed

Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers

Healthy

United Kingdom
BioCryst Pharmaceuticals

Terminated

BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (REDEEM-1)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Hungary, France, Italy, Spain
Regeneron Pharmaceuticals

Terminated

Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (ACCESS 2)

Paroxysmal Nocturnal Hemoglobinuria

United States
Regeneron Pharmaceuticals

Recruiting

A C5 Inhibitor-controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy (ACCESS-1)

Paroxysmal Nocturnal Hemoglobinuria

Mexico, Korea, Republic of, Turkey, Italy, United Kingdom, Thailand, Poland, Singapore, Spain, Taiwan, Canada, Japan, United States, Malaysia, Greece, Romania, Hungary
Ain Shams University

Unknown

Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19

Coronavirus Disease (COVID-19)

Egypt

Search clinical trials for: ALXN1101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations